This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Transcriptional CDK inhibitors, CYC065 and THZ1 promote Bim-dependent apoptosis in primary and recurrent GBM through cell cycle arrest and Mcl-1 downregulation
Cell Death & Disease Open Access 03 August 2021
-
Berberine affects mitochondrial activity and cell growth of leukemic cells from chronic lymphocytic leukemia patients
Scientific Reports Open Access 05 October 2020
-
Quercetin downregulates Mcl-1 by acting on mRNA stability and protein degradation
British Journal of Cancer Open Access 12 July 2011
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kitada S, Andersen J, Akar S, Zapata JM, Takayama S, Krajewski S et al. Expression of apoptosis-regulating proteins in chronic lymphocytic leukemia: correlations with in vitro and in vivo chemoresponses. Blood 1998; 91: 3379–3389.
Hussain SR, Cheney CM, Johnson AJ, Lin TS, Grever MR, Caligiuri MA et al. Mcl-1 is a relevant therapeutic target in acute and chronic lymphoid malignancies: down-regulation enhances rituximab-mediated apoptosis and complement-dependent cytotoxicity. Clin Cancer Res 2007; 13: 2144–2150.
Isomoto H, Kobayashi S, Werneburg NW, Bronk SF, Guicciardi ME, Frank DA et al. Interleukin-6 upregulates myeloid cell leukaemia-1 expression through a STAT3 pathway in cholangiocarcinome cells. Hepatology 2005; 42: 1329–1338.
Beillard E, Pallisgaard N, van der Velden VH, Bi W, Dee R, van der Schoot E et al. Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using ‘real-time’ quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR)—a Europe against cancer program. Leukemia 2003; 17: 2474–2486.
Montserrat E . New prognostic markers in CLL. Hematol Am Soc Hematol Educ Program 2006, 279–284.
Kienle DL, Korz C, Hosch B, Benner A, Mertens D, Habermann A et al. Evidence for distinct pathomechanisms in genetic subgroups of chronic lymphocytic leukemia revealed by quantitative expression analysis of cell cycle, activation, and apoptosis-associated genes. J Clin Oncol 2005; 23: 3780–3792.
Aguilar-Santelises M, Rottenberg ME, Lewin N, Mellstedt H, Jondal M . Bcl-2, Bax and p53 expression in B-CLL in relation to in vitro survival and clinical progression. Int J Cancer 1996; 69: 114–119.
Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A . Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112–121.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Véronèse, L., Tournilhac, O., Verrelle, P. et al. Low MCL-1 mRNA expression correlates with prolonged survival in B-cell chronic lymphocytic leukemia. Leukemia 22, 1291–1293 (2008). https://doi.org/10.1038/sj.leu.2405052
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2405052